CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $4,425,400 | -54.5% | 507,500 | -67.3% | 0.87% | -54.4% |
Q4 2022 | $9,718,500 | +247.3% | 1,550,000 | +93.9% | 1.90% | +182.6% |
Q3 2022 | $2,798,000 | -78.9% | 799,439 | -20.0% | 0.67% | -48.7% |
Q1 2019 | $13,265,000 | +18.8% | 998,841 | -29.6% | 1.31% | -6.9% |
Q4 2018 | $11,164,000 | – | 1,418,489 | – | 1.41% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |